Overview

Zithromax EV in Community-Acquired Pneumonia (CAP)

Status:
Completed
Trial end date:
2005-09-01
Target enrollment:
Participant gender:
Summary
The intravenous (IV) regimen containing azithromycin (Zithromax) plus ampicillin-sulbactam is consistent with current guidelines for the treatment of CAP. In fact the International guidelines for the treatment of CAP in hospitalised patients suggests the use of a combination between a b-lactam and a macrolide. This trial will allow investigators to evaluate the efficacy of azithromycin plus ampicillin-sulbactam in the treatment of hospitalized subjects with community acquired pneumonia. In addition, this trial will allow investigators to evaluate the safety and toleration of combination therapy.
Phase:
Phase 4
Details
Lead Sponsor:
Pfizer
Treatments:
Ampicillin
Azithromycin
Sulbactam
Sultamicillin